Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus

M. Hearth-Holmes, B. A. Baethge, L. Broadwell, R. E. Wolf

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: To evaluate dietary therapy in the treatment of hyperlipidemia in patients with systemic lupus erythematosus (SLE). Methods: Using the National Cholesterol Education Program (NCEP) guidelines, we screened 89 patients with SLE for hyperlipidemia. Step 1 dietary therapy was instituted in 28 patients as recommended by the NCEP. Twenty-six patients failed Step 1 intervention and received Step 2 dietary therapy for an additional 3 months. Twenty-nine control patients with SLE were tested for hyperlipidemia. Results: The 89 patients with SLE (94% women, 77% black) had a mean age of 37.2 years. Fasting. values were total cholesterol (TC) 6.22 ± 0.16 mmol/l (240.9 ± 6.0 mg/dl), low density lipoprotein cholesterol (LDL-C) 4.08 ± 0.14 mmol/l, (157.6 ± 5.3 mg/dl), high density lipoprotein (HDL-C) 1.37 ± 0.08 mmol/l (53.0 ± 3.1 mg/dl), and triglyceride (TG) 1.71 ± 0.12 mmol/l, (151.9 ± 10.6 mg/dl). The mean dose of prednisone was 14.2 ± 1.6 mg/day. Prednisone dose correlated with levels of TC (p < 0.01) by linear regression. The 28 patients receiving Step 1 dietary intervention had TC 6.11 ± 0.19 mmol/l (236.4 ± 7.3 mg/dl), LDL-C 4.05 ± 0.19 mmol/l (156.6 ± 7.5 mg/dl), HDL-C 1.31 ± 0.08 mmol/l (50.7 ± 3.0 mg/dl), and TG 1.64 ± 0.12 mmol/l (145.4. ± 10.3 mg/dl). The 26 patients receiving Step 2 dietary intervention had TC 5.84 ± 0.17 mmol/l (226.0 ± 6.6 mg/dl), LDL-C 3.83 ± 0.19 mmol/l (148.0 ± 7.2 mg/dl), HDL-C 1.25 ± 0.08 mmol/l (48.5 ± 3.2 mg/dl), and TG 1.66 ± 0.15 mmol/l (147.1 ± 13.4 mg/dl). The mean prednisone dose was 14.8 ± 3.0 mg/day for both study groups. There was no significance between prednisone doses in all groups studied (p = 0.08). After 6 months of dietary therapy, there was a significant decrease in only the TC (p = 0.158). Conclusion: TC correlated directly with the prednisone dose. Six months of dietary intervention was required to significantly decrease the TC. Further management of hyperlipidemia will probably require drug intervention.

Original languageEnglish (US)
Pages (from-to)450-454
Number of pages5
JournalJournal of Rheumatology
Volume22
Issue number3
StatePublished - Apr 5 1995

Fingerprint

Hyperlipidemias
Systemic Lupus Erythematosus
Cholesterol
Prednisone
LDL Cholesterol
Triglycerides
Therapeutics
Education
HDL Lipoproteins
Linear Models
Fasting
Guidelines
Pharmaceutical Preparations

Keywords

  • Cholesterol diet
  • Hyperlipidemia
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. / Hearth-Holmes, M.; Baethge, B. A.; Broadwell, L.; Wolf, R. E.

In: Journal of Rheumatology, Vol. 22, No. 3, 05.04.1995, p. 450-454.

Research output: Contribution to journalArticle

Hearth-Holmes, M. ; Baethge, B. A. ; Broadwell, L. ; Wolf, R. E. / Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. In: Journal of Rheumatology. 1995 ; Vol. 22, No. 3. pp. 450-454.
@article{adf2410531944fd7b677b9b29d0a6bc9,
title = "Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus",
abstract = "Objective: To evaluate dietary therapy in the treatment of hyperlipidemia in patients with systemic lupus erythematosus (SLE). Methods: Using the National Cholesterol Education Program (NCEP) guidelines, we screened 89 patients with SLE for hyperlipidemia. Step 1 dietary therapy was instituted in 28 patients as recommended by the NCEP. Twenty-six patients failed Step 1 intervention and received Step 2 dietary therapy for an additional 3 months. Twenty-nine control patients with SLE were tested for hyperlipidemia. Results: The 89 patients with SLE (94{\%} women, 77{\%} black) had a mean age of 37.2 years. Fasting. values were total cholesterol (TC) 6.22 ± 0.16 mmol/l (240.9 ± 6.0 mg/dl), low density lipoprotein cholesterol (LDL-C) 4.08 ± 0.14 mmol/l, (157.6 ± 5.3 mg/dl), high density lipoprotein (HDL-C) 1.37 ± 0.08 mmol/l (53.0 ± 3.1 mg/dl), and triglyceride (TG) 1.71 ± 0.12 mmol/l, (151.9 ± 10.6 mg/dl). The mean dose of prednisone was 14.2 ± 1.6 mg/day. Prednisone dose correlated with levels of TC (p < 0.01) by linear regression. The 28 patients receiving Step 1 dietary intervention had TC 6.11 ± 0.19 mmol/l (236.4 ± 7.3 mg/dl), LDL-C 4.05 ± 0.19 mmol/l (156.6 ± 7.5 mg/dl), HDL-C 1.31 ± 0.08 mmol/l (50.7 ± 3.0 mg/dl), and TG 1.64 ± 0.12 mmol/l (145.4. ± 10.3 mg/dl). The 26 patients receiving Step 2 dietary intervention had TC 5.84 ± 0.17 mmol/l (226.0 ± 6.6 mg/dl), LDL-C 3.83 ± 0.19 mmol/l (148.0 ± 7.2 mg/dl), HDL-C 1.25 ± 0.08 mmol/l (48.5 ± 3.2 mg/dl), and TG 1.66 ± 0.15 mmol/l (147.1 ± 13.4 mg/dl). The mean prednisone dose was 14.8 ± 3.0 mg/day for both study groups. There was no significance between prednisone doses in all groups studied (p = 0.08). After 6 months of dietary therapy, there was a significant decrease in only the TC (p = 0.158). Conclusion: TC correlated directly with the prednisone dose. Six months of dietary intervention was required to significantly decrease the TC. Further management of hyperlipidemia will probably require drug intervention.",
keywords = "Cholesterol diet, Hyperlipidemia, Systemic lupus erythematosus",
author = "M. Hearth-Holmes and Baethge, {B. A.} and L. Broadwell and Wolf, {R. E.}",
year = "1995",
month = "4",
day = "5",
language = "English (US)",
volume = "22",
pages = "450--454",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "3",

}

TY - JOUR

T1 - Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus

AU - Hearth-Holmes, M.

AU - Baethge, B. A.

AU - Broadwell, L.

AU - Wolf, R. E.

PY - 1995/4/5

Y1 - 1995/4/5

N2 - Objective: To evaluate dietary therapy in the treatment of hyperlipidemia in patients with systemic lupus erythematosus (SLE). Methods: Using the National Cholesterol Education Program (NCEP) guidelines, we screened 89 patients with SLE for hyperlipidemia. Step 1 dietary therapy was instituted in 28 patients as recommended by the NCEP. Twenty-six patients failed Step 1 intervention and received Step 2 dietary therapy for an additional 3 months. Twenty-nine control patients with SLE were tested for hyperlipidemia. Results: The 89 patients with SLE (94% women, 77% black) had a mean age of 37.2 years. Fasting. values were total cholesterol (TC) 6.22 ± 0.16 mmol/l (240.9 ± 6.0 mg/dl), low density lipoprotein cholesterol (LDL-C) 4.08 ± 0.14 mmol/l, (157.6 ± 5.3 mg/dl), high density lipoprotein (HDL-C) 1.37 ± 0.08 mmol/l (53.0 ± 3.1 mg/dl), and triglyceride (TG) 1.71 ± 0.12 mmol/l, (151.9 ± 10.6 mg/dl). The mean dose of prednisone was 14.2 ± 1.6 mg/day. Prednisone dose correlated with levels of TC (p < 0.01) by linear regression. The 28 patients receiving Step 1 dietary intervention had TC 6.11 ± 0.19 mmol/l (236.4 ± 7.3 mg/dl), LDL-C 4.05 ± 0.19 mmol/l (156.6 ± 7.5 mg/dl), HDL-C 1.31 ± 0.08 mmol/l (50.7 ± 3.0 mg/dl), and TG 1.64 ± 0.12 mmol/l (145.4. ± 10.3 mg/dl). The 26 patients receiving Step 2 dietary intervention had TC 5.84 ± 0.17 mmol/l (226.0 ± 6.6 mg/dl), LDL-C 3.83 ± 0.19 mmol/l (148.0 ± 7.2 mg/dl), HDL-C 1.25 ± 0.08 mmol/l (48.5 ± 3.2 mg/dl), and TG 1.66 ± 0.15 mmol/l (147.1 ± 13.4 mg/dl). The mean prednisone dose was 14.8 ± 3.0 mg/day for both study groups. There was no significance between prednisone doses in all groups studied (p = 0.08). After 6 months of dietary therapy, there was a significant decrease in only the TC (p = 0.158). Conclusion: TC correlated directly with the prednisone dose. Six months of dietary intervention was required to significantly decrease the TC. Further management of hyperlipidemia will probably require drug intervention.

AB - Objective: To evaluate dietary therapy in the treatment of hyperlipidemia in patients with systemic lupus erythematosus (SLE). Methods: Using the National Cholesterol Education Program (NCEP) guidelines, we screened 89 patients with SLE for hyperlipidemia. Step 1 dietary therapy was instituted in 28 patients as recommended by the NCEP. Twenty-six patients failed Step 1 intervention and received Step 2 dietary therapy for an additional 3 months. Twenty-nine control patients with SLE were tested for hyperlipidemia. Results: The 89 patients with SLE (94% women, 77% black) had a mean age of 37.2 years. Fasting. values were total cholesterol (TC) 6.22 ± 0.16 mmol/l (240.9 ± 6.0 mg/dl), low density lipoprotein cholesterol (LDL-C) 4.08 ± 0.14 mmol/l, (157.6 ± 5.3 mg/dl), high density lipoprotein (HDL-C) 1.37 ± 0.08 mmol/l (53.0 ± 3.1 mg/dl), and triglyceride (TG) 1.71 ± 0.12 mmol/l, (151.9 ± 10.6 mg/dl). The mean dose of prednisone was 14.2 ± 1.6 mg/day. Prednisone dose correlated with levels of TC (p < 0.01) by linear regression. The 28 patients receiving Step 1 dietary intervention had TC 6.11 ± 0.19 mmol/l (236.4 ± 7.3 mg/dl), LDL-C 4.05 ± 0.19 mmol/l (156.6 ± 7.5 mg/dl), HDL-C 1.31 ± 0.08 mmol/l (50.7 ± 3.0 mg/dl), and TG 1.64 ± 0.12 mmol/l (145.4. ± 10.3 mg/dl). The 26 patients receiving Step 2 dietary intervention had TC 5.84 ± 0.17 mmol/l (226.0 ± 6.6 mg/dl), LDL-C 3.83 ± 0.19 mmol/l (148.0 ± 7.2 mg/dl), HDL-C 1.25 ± 0.08 mmol/l (48.5 ± 3.2 mg/dl), and TG 1.66 ± 0.15 mmol/l (147.1 ± 13.4 mg/dl). The mean prednisone dose was 14.8 ± 3.0 mg/day for both study groups. There was no significance between prednisone doses in all groups studied (p = 0.08). After 6 months of dietary therapy, there was a significant decrease in only the TC (p = 0.158). Conclusion: TC correlated directly with the prednisone dose. Six months of dietary intervention was required to significantly decrease the TC. Further management of hyperlipidemia will probably require drug intervention.

KW - Cholesterol diet

KW - Hyperlipidemia

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0028969505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028969505&partnerID=8YFLogxK

M3 - Article

C2 - 7783060

AN - SCOPUS:0028969505

VL - 22

SP - 450

EP - 454

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 3

ER -